Clene Inc.

NasdaqCM:CLNN

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

🔬 Chemicals & Advanced Materials

💊 Pharmaceuticals

Location

United States

Market Cap

USD 38.45 M

Share Price

USD 4.28

Avg Daily Volume

88,092

Change (1 day)

-2.06%

Change (1 year)

-45.27%

Change (YTD)

-19.40%

Clene Inc. Operating Income Margin for the Trailing 12 Months (TTM) ending March 31, 2025: -7,982.00%

Clene Inc. Operating Income Margin is -7,982.00% for the Trailing 12 Months (TTM) ending March 31, 2025. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.

Clene Inc. Operating Income Margin for the Trailing 12 Months (TTM) ending March 31, 2023 was -7,767.09%, a -17.61% change year over year.
Clene Inc. Operating Income Margin for the Trailing 12 Months (TTM) ending March 31, 2022 was -9,427.59%, a 17.90% change year over year.
Clene Inc. Operating Income Margin for the Trailing 12 Months (TTM) ending March 31, 2021 was -7,996.28%, a -66.94% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Operating Income Margin	Gross Profit Margin	EBIT Margin	EBITDA Margin

NasdaqCM: CLNN

Clene Inc.

CEO	Mr. Robert Etherington MBA
IPO Date	Oct. 18, 2018
Location	United States
Headquarters	6550 South Millrock Drive
Employees	75
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 🔬 Chemicals & Advanced Materials 💊 Pharmaceuticals

Description

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.